KRYSTAL BIOTECH INC (KRYS)
US5011471027 - Common Stock
KRYS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KRYS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, KRYS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year KRYS has reported negative net income.
In the past year KRYS has reported a negative cash flow from operations.
In the past 5 years KRYS reported 4 times negative net income.
In the past 5 years KRYS always reported negative operating cash flow.
1.2 Ratios
KRYS has a Return On Assets of 1.34%. This is amongst the best in the industry. KRYS outperforms 94.71% of its industry peers.
The Return On Equity of KRYS (1.40%) is better than 94.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 1.4% | ||
| ROIC | N/A |
ROA(3y)-11.61%
ROA(5y)-10.86%
ROE(3y)-12.37%
ROE(5y)-11.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 21.56%, KRYS belongs to the top of the industry, outperforming 97.95% of the companies in the same industry.
Looking at the Gross Margin, with a value of 93.89%, KRYS belongs to the top of the industry, outperforming 95.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 21.56% | ||
| GM | 93.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KRYS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KRYS has more shares outstanding
KRYS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
KRYS has an Altman-Z score of 68.80. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
KRYS has a better Altman-Z score (68.80) than 98.63% of its industry peers.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 68.8 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
KRYS has a Current Ratio of 17.76. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a Current ratio of 17.76. This is amongst the best in the industry. KRYS outperforms 93.86% of its industry peers.
A Quick Ratio of 17.55 indicates that KRYS has no problem at all paying its short term obligations.
KRYS has a Quick ratio of 17.55. This is amongst the best in the industry. KRYS outperforms 93.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.55 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.61%, which is quite impressive.
EPS 1Y (TTM)24.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q124%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 42.58% on average per year.
The Revenue is expected to grow by 84.55% on average over the next years. This is a very strong growth
EPS Next Y138.17%
EPS Next 2Y79.12%
EPS Next 3Y65.84%
EPS Next 5Y42.58%
Revenue Next Year590.12%
Revenue Next 2Y238.59%
Revenue Next 3Y155.48%
Revenue Next 5Y84.55%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KRYS. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 123.04 indicates a quite expensive valuation of KRYS.
94.20% of the companies in the same industry are more expensive than KRYS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.92, KRYS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 123.04 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 65.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.12%
EPS Next 3Y65.84%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KRYSTAL BIOTECH INC
NASDAQ:KRYS (5/1/2024, 7:06:35 PM)
After market: 159.67 0 (0%)159.67
+6.55 (+4.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.55B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 123.04 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 1.4% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 21.56% | ||
| GM | 93.89% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)24.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y138.17%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y